UroGen Pharma Ltd. (URGN)
29.79
-0.08
(-0.27%)
USD |
NASDAQ |
Nov 18, 16:00
30.05
+0.26
(+0.87%)
After-Hours: 07:36
UroGen Pharma Enterprise Value : 1.565B for Nov. 18, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 18, 2026 | 1.565B |
| November 17, 2026 | 1.569B |
| November 16, 2026 | 1.482B |
| November 13, 2026 | 1.388B |
| November 12, 2026 | 1.398B |
| November 11, 2026 | 1.384B |
| November 10, 2026 | 1.346B |
| November 09, 2026 | 1.394B |
| November 06, 2026 | 1.318B |
| November 05, 2026 | 1.366B |
| November 04, 2026 | 1.513B |
| November 03, 2026 | 1.791B |
| November 02, 2026 | 1.789B |
| October 30, 2026 | 1.709B |
| October 29, 2026 | 1.746B |
| October 28, 2026 | 1.759B |
| October 27, 2026 | 1.767B |
| October 26, 2026 | 1.773B |
| October 23, 2026 | 1.795B |
| October 22, 2026 | 1.828B |
| October 21, 2026 | 1.844B |
| October 20, 2026 | 1.821B |
| October 19, 2026 | 1.779B |
| October 16, 2026 | 1.799B |
| October 15, 2026 | 1.899B |
| Date | Value |
|---|---|
| October 14, 2026 | 1.898B |
| October 13, 2026 | 1.980B |
| October 12, 2026 | 1.981B |
| October 09, 2026 | 1.910B |
| October 08, 2026 | 1.917B |
| October 07, 2026 | 2.100B |
| October 06, 2026 | 2.136B |
| October 05, 2026 | 2.202B |
| October 02, 2026 | 2.134B |
| October 01, 2026 | 2.093B |
| September 30, 2026 | 2.096B |
| September 29, 2026 | 2.064B |
| September 28, 2026 | 2.086B |
| September 25, 2026 | 2.108B |
| September 24, 2026 | 2.102B |
| September 23, 2026 | 2.121B |
| September 22, 2026 | 2.176B |
| September 21, 2026 | 2.198B |
| September 18, 2026 | 2.200B |
| September 17, 2026 | 2.235B |
| September 16, 2026 | 2.212B |
| September 15, 2026 | 2.127B |
| September 14, 2026 | 2.171B |
| September 11, 2026 | 2.154B |
| September 10, 2026 | 2.151B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Xencor, Inc. | 2.326B |
| MeiraGTx Holdings Plc | 761.54M |
| Ironwood Pharmaceuticals, Inc. | 1.041B |
| Viking Therapeutics, Inc. | 2.632B |
| IDEAYA Biosciences, Inc. | 1.751B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -1.462M |
| Revenue (Quarterly) | 89.00M |
| Total Expenses (Quarterly) | 90.46M |
| EPS Diluted (Quarterly) | -0.0289 |
| Gross Profit Margin (Quarterly) | 91.57% |
| Profit Margin (Quarterly) | -1.64% |
| Earnings Yield | -4.46% |
| Normalized Earnings Yield | -4.461 |